Category list : Antineoplastic agents
Sort by: Newest first Oldest first A-Z Z-A
-
Combination drug approved in Europe for metastatic colorectal cancer
A new combination oral treatment, Lonsurf, has been granted a marketing authorisation for adults with metastatic colorectal cancer by the European Commission.
-
Alectinib approved by FDA for ALK-positive lung cancer Subscription
Alectinib, a new drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, has been approved by the US Food and Drug Administration.
-
Don't overlook opportunities to repurpose existing drugs Subscription
More needs to be done to incentivise research into new indications for existing medicines.
-
Avastin indicated for cervical cancer Subscription
Avastin (bevacizumab;Roche) is now licensed, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. This is in addition to its use in advanced non-small cell lung cancer or advanced cancers of the bowel, breast or kidney.
-
NSAIDs may help protect against skin cancer Subscription
The use of non-steroidal anti-inflammatory drugs (NSAIDs), a class of medicines used to treat pain and inflammation, is associated with a reduced risk of developing cutaneous squamous cell carcinoma (SCC), a type of skin cancer, research suggests.
-
Chemoprevention with tamoxifen cuts risk of breast cancer by almost 30% Subscription
Tamoxifen used in primary prevention cuts the risk of breast cancer by around 30% and this benefit lasts for at least 20 years, a long-term follow-up of the International Breast Cancer Intervention Study shows.
-
Lipophilic bisphosphonates used to target lung cancer Subscription
A new generation of lipophilic bisphosphonates has been designed to target cancer, with a zoledronic acid analogue demonstrating efficacy against lung adenocarcinoma.
-
Ibrutinib launched for treatment of mantle cell lymphoma and chronic lymphocytic leukaemia Subscription
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been launched in the UK for the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia.
-
Clinical Pharmacist's monthly news round-up: the top 10 in the past month Subscription
What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month…
-
Criticism voiced over new rules for Cancer Drugs Fund Subscription
Cancer charities and the pharmaceutical industry have expressed concerns over the way cancer medicines are appraised after a revised process for assessing drugs available through the Cancer Drugs Fund was published by NHS England.
-
Wales will not have a Cancer Drugs Fund, health minister says Subscription
Wales will not have a Cancer Drugs Fund, despite a 98,000-signature petition calling for equity of access to cancer drugs for patients in England and Wales being handed to the Welsh Assembly on 5 November 2014.
-
Adding bevacizumab to triple therapy improves outcome in colorectal cancer Subscription
Patient outcome is improved when bevacizumab is given with a triple- rather than a two-drug combination in metastatic colorectal cancer.
-
Green light for first treatment to target ovarian cancer with BRCA mutation Subscription
The European Medicines Agency has recommended that Lynparza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options.
-
Scientific advances are not translating into new cancer drugs, expert warns Subscription
The global system for discovering new cancer drugs is failing to turn scientific advances into innovative new medicines, Paul Workman, interim chief executive of The Institute of Cancer Research in London has warned.
-
Treatment tested for patients with visceral leishmaniasis and HIV in Africa Subscription
The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.
-
Cancer drugs approved faster in the United States than in Europe or Canada Subscription
Regulatory agencies in the United States take less time to approve new cancer drugs than those in Europe or Canada, according to new research.
-
New melanoma treatment approved by NICE Subscription
The National Institute for Health and care Excellence has issued draft guidance recommending that dabrafenib should be available on the NHS for the treatment of melanoma that has spread or can’t be completely removed by surgery in patients with a BRAF gene mutation.
-
Promising results for lenalidomide plus dexamethasone in myeloma Subscription
A trial involving more than 1,600 patients with multiple myeloma showed improvement in progression-free survival with a new combination therapy.
-
Rare blood cancer treatments recommended for approval by the EMA
The European Medicines Agency has approved two new medicines, ibrutinib (Janssen-Cilag’s Imbruvica) and idelalisib (Gilead Science’s Zydelig), for adult patients with rare blood cancers.
-
Exposure to light at night may reduce effectiveness of breast cancer drug tamoxifen
Keeping the lights on during the night may cause breast cancer patients to become resistant to a commonly-prescribed treatment.
Show 10 per page20 per page50 per page
